One Year Later: Our ‘No-Brainer' Rigetti Call Doubled. What to Do Now.

Rigetti’s thesis largely played out, with the stock rising from $8.86 to $18.01 over the one-year period and hitting a peak near $58.15, helped by Cepheus-1-36Q, 99.9% two-qubit gate fidelity, and multiple commercial and partnership wins. However, valuation remains stretched at a $5.8 billion market cap versus just $7.09 million of 2025 revenue and a $216.21 million net loss, while dilution increased shares from 171.9 million to 298.3 million. The article is constructive on the long-term quantum roadmap but cautious on near-term entry due to volatility, shrinking revenue, and weak fundamentals.

Analysis

RGTI has moved from a pure science-story to a capital-markets trade on proof-of-execution, but the market is now pricing in a steep path to monetization that the business cannot yet validate. The key second-order issue is that each technical milestone raises the valuation bar faster than it expands near-term revenue, so incremental good news can become a source of selling if it does not convert into repeatable, high-margin bookings. In that sense, the stock is less a quantum winner-take-all option and more a reflexive financing vehicle whose equity currency improves its ability to stay relevant.

The real competitive benefit accrues to the ecosystem around RGTI, especially NVDA, which gets a strategic “quantum platform” halo without needing quantum revenue to matter in the next 12-24 months. For suppliers and partners, the upside is asymmetric: they can monetize development spend, integration work, and enterprise pilots while avoiding the binary commercialization risk borne by RGTI shareholders. That creates a subtle loser/ winner split where the infrastructure layer can win even if most pure-play quantum names remain structurally unprofitable.

The main risk is not technical failure; it is time compression. If commercialization slips by even a few quarters, dilution risk and sentiment deterioration can overwhelm product progress because the stock is trading on narrative momentum, not cash-flow durability. The opposite catalyst is a credible conversion event — multi-system orders, recurring service revenue, or a named enterprise deployment pipeline — which would justify a re-rating over months rather than days.

The contrarian view is that the drawdown from the highs may still be insufficiently discounted if the market has begun to anchor on “eventually inevitable” quantum adoption. In speculative growth names, the first leg is usually driven by capability proof, but the second leg requires revenue proof; RGTI has not cleared that threshold. That makes the current setup attractive for trading volatility, but fragile for long-duration ownership unless position size reflects a much higher probability of further dilution or multiple compression.

Key Decisions for Investors

• Trim RGTI longs into strength; keep only a house-money residual position for 6-12 months. Risk/reward is poor for full-size ownership until bookings convert into recurring revenue and dilution risk stops dominating the capital structure.
• For new exposure, prefer a defined-risk structure in RGTI: buy 3-6 month call spreads rather than stock. This keeps upside to a sentiment squeeze while capping downside if the next catalyst disappoints.
• Long NVDA / short a basket of speculative quantum pure plays over 3-6 months. NVDA captures ecosystem optionality with less binary execution risk, while the basket is vulnerable to funding and commercialization delays.
• If holding RGTI, hedge with near-dated puts around the next earnings or order-update window. The stock’s reaction function suggests revenue misses can produce outsized declines within days.
• Watch for a fresh primary raise or aggressive ATM usage; if announced, reduce exposure immediately. That would signal the equity is being used as operating capital, which typically compresses multiples first and sentiment second.